Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

mTOR Inhibitors for Small Cell Lung Cancer
Author
Howard (Jack) West, MD

We've covered the modest activity of a few mTOR inhibitors in NSCLC (see prior post), so now we'll turn to SCLC. Everolimus, an oral mTOR inhibitor, has been studied at 10 mg by mouth daily in patients with relapsed SCLC and had received 1 or 2 prior regimens and no brain metastases (abstract here). The investigators did a preliminary analysis of 19 patients, among whom there were no responses, and only 3 achieved stable disease. Though tolerated well enough, there wasn't enough of a signal to move forward with it. The IV mTOR inhibitor temsirolimus (Torisel) has also been studied in a more favorable prognosis scenario of maintenance therapy after a good response to first line chemo for extensive stage SCLC (abstract here). A total of 85 patients were treated with either of two doses, 25 mg IV weekly, or ten times that amount, 250 mg IV weekly. The median survival of 8 months was reasonable, but it was notably better at the higher dose (6.6 months vs. 9.5 months). The problem was that these patients also tend to do well, and the patients receiving temsirolimus didn't do better than the investigators would have expected otherwise. Because of this, there was little enthusiasm for continuing with it as a single agent in SCLC, but there was more interest in adding it to chemo for SCLC.

In fact, there is a study moving forward, being sponsored by Novartis, the makers of everolimus, the oral mTOR inhibitor, in combination with cisplatin and etoposide as first line therapy for extensive stage SCLC. The first portion is primarily checking whether it's safe and feasible to combine these agents as a triplet, and there is more information about that trial here.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on